Oliver Press
Oliver Press was a prominent American oncologist and hematologist known for his significant contributions to the field of cancer research, particularly in the treatment of lymphoma. He held various academic and clinical positions throughout his career, making substantial advancements in immunotherapy and radioimmunotherapy.
Early Life and Education[edit | edit source]
Oliver Press was born in New York City. He pursued his undergraduate studies at Harvard University, where he earned a degree in biochemistry. He then attended Case Western Reserve University School of Medicine, where he obtained his M.D. and Ph.D. degrees.
Career[edit | edit source]
Press began his medical career with a residency in internal medicine at the University of Washington. He subsequently completed a fellowship in hematology and oncology at the same institution. He joined the faculty at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, where he held various positions, including Professor of Medicine.
Research Contributions[edit | edit source]
Oliver Press was renowned for his pioneering work in the development of radioimmunotherapy for the treatment of non-Hodgkin lymphoma. His research focused on the use of monoclonal antibodies to deliver targeted radiation to cancer cells, minimizing damage to surrounding healthy tissue. This approach significantly improved the outcomes for patients with relapsed or refractory lymphoma.
Awards and Honors[edit | edit source]
Throughout his career, Press received numerous awards and honors, including the American Society of Clinical Oncology's Gianni Bonadonna Breast Cancer Award and the American Association for Cancer Research's Joseph H. Burchenal Memorial Award for outstanding achievements in clinical cancer research.
Personal Life[edit | edit source]
Oliver Press was married and had two children. He was known for his dedication to his family and his passion for sailing and photography.
Death[edit | edit source]
Oliver Press passed away on September 29, 2017, after a battle with prostate cancer. His legacy continues through the many lives he touched and the advancements he made in the field of oncology.
Related Pages[edit | edit source]
- Oncology
- Hematology
- Lymphoma
- Immunotherapy
- Radioimmunotherapy
- Fred Hutchinson Cancer Research Center
- University of Washington School of Medicine
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
